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Distinct oncogenic signalling cascades have been associated with non-Hodgkin lymphoma. 
ERK1/2  signalling  elicits  both  transcriptional  and  post-transcriptional  effects  through 
phosphorylation  of  numerous  substrates.  Here  we  report  a  novel  molecular  relationship   
between ERK1/2 and CHK2, a protein kinase that is a key mediator of the DnA damage   
checkpoint  that  responds  to  DnA  double-strand  breaks.  our  studies  are  the  first  to 
demonstrate the co-localization and overexpression of ERK1/2 and CHK2 in diffuse large B-cell 
lymphoma (DLBCL). The physical interaction between ERK and CHK2 was highly dependent 
on phosphorylated Thr 68 of CHK2. Concurrent administration of an ERK inhibitor enhances 
the antitumour activity of CHK2 inhibition in both a human DLBCL xenograft model as well 
as  primary  human  DLBCL  cells.  our  data  suggest  a  functional  interaction  between  ERK 
and CHK2 and support the potential combined therapeutic targeting of ERK and CHK2 in   
human DLBCL. 
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R
ecent  evidence  implicates  DNA  repair  and  the  genome 
integrity checkpoints as major barriers whose deregulation 
is largely responsible for the enhanced genetic instability of 
cancer cells1. The CHK2 kinase is a key mediator of the DNA dam-
age checkpoint that responds to DNA double-strand breaks (DSBs). 
DNA  DSBs  induce  the  activation  of  ATM  (ataxia  telangiectasia 
mutated), which subsequently phosphorylates CHK2 on threonine 
68 (ref. 2). Phosphorylation of CHK2 induces CHK2 dimerization, 
which  is  required  for  CHK2  activity.  Once  dimerized,  CHK2  is 
further activated by autophosphorylation in trans at residues 383, 
387, 546 and 516 (ref. 2). CHK2 phosphorylates a range of proteins   
involved  in  cell  cycle  control  and  apoptosis  including  cdc25A, 
cdc25C,  Mdmx,  p53,  BRCA1,  PML,  E2F1,  and  phosphatase  2A   
(ref. 2). CHK2 also mediates stabilization of the FoxM1 transcrip-
tion  factor  to  stimulate  expression  of  DNA  repair  genes3.  Cells 
derived from CHK2-deficient mice exhibit defects in their ability to 
delay entry into S phase, sustain a G2 cell cycle arrest, and undergo   
apoptosis in response to DNA damage4. It is newly reported that 
CHK2, independent of p53 and DNA damage, is required for proper 
progression of mitosis, and for the maintenance of chromosomal 
stability in human somatic cells5. CHK2 can also protect genome 
integrity by promoting apoptosis through interacting with a number 
of other substrates. Inhibition of CHK2 by transfection of a domi-
nant-negative CHK2 mutant or a chemical inhibitor, debromohyme-
nialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, 
and allows for a prolonged activation of Cdk1 (ref. 6). Under these 
conditions, multinuclear HeLa syncytia do not arrest at the G2/M 
boundary  and  rather  enter  mitosis  and  subsequently  die  during   
the metaphase of the cell cycle6. Therefore, inhibition of CHK2 can 
sensitize proliferating cells to chemotherapy-induced apoptosis.
The first indication of the role of CHK2 in cancer came from a 
study that reported the presence of germline mutations in CHK2 
in families with Li-Fraumeni Syndrome7. It has been subsequently 
shown that defects of CHK2 occur in subsets of diverse sporadic 
malignancies and predispose to several types of hereditary carcino-
mas8. However, there is increasing evidence that CHK2 is a cancer 
susceptibility gene, but not a tumour suppressor gene in the classical 
sense9,10. CHK2 is aberrantly and constitutively activated in invasive 
urinary bladder carcinomas, and the putative proapoptotic check-
point signalling can be disabled by inactivation of CHK2 and/or p53 
tumour suppressors in subsets of these tumours8. More than 50% 
of CHK2 was phosphorylated at Thr68 in surgically resected lung 
and breast tumour specimens from otherwise untreated patients11. 
Targeting of CHK2 with small interfering RNA prevents survivin 
release from the mitochondria and enhanced apoptosis following 
induction of DNA damage by ionizing radiation (IR) or doxorubicin 
and inhibits the growth of resistant in vivo tumours. Expression of   
a  dominant  negative  CHK2  potentiates  cytotoxicity  in  HCT116 
colon  carcinoma  cells  to  doxorubicin9.  These  findings  suggested 
that activated CHK2 manifests both tumour-suppressor functions 
as well as the capacity to promote tumour and cell survival9,12. Rela-
tively little is known about the contribution of CHK2 or the efficacy 
of CHK2 inhibitor in diffuse large B-cell lymphoma (DLBCL).
The  extracellular  signal-regulated  kinases  1  and  2  (ERK1/2) 
regulate cell proliferation and survival. Deregulation of ERK signal-
ling is associated with genomic instability and cancer13. In earlier 
work,  we  showed  that  ERK  inhibition  induced  the  apoptosis  of 
human DLBCL cells and has marked antitumour activity in human   
DLBCL xenograft models, implying the potential role of target-
ing ERK in the therapy of DLBCL14. It was shown that disruption   
of ERK1/2 activation by pharmacologic MEK1/2 inhibitors results 
in  a  dramatic  increase  in  apoptosis  of  hematopoietic  malignant 
cells15,16.
Considering that there is little data on CHK2 and ERK signalling 
in lymphoid malignancies, in this study, we explored the molecular 
mechanisms underlying the functional interaction between ERK2 
and CHK2. Furthermore, we investigated the potential therapeutic   
efficacy of combining ERK and CHK2 inhibitors in a pre-clinical   
model  of  DLBCL.  We  report  here  that  the  interaction  between 
ERK and CHK2 was highly dependent on phosphorylated Thr 68 
of CHK2 and that concurrent administration of an ERK inhibitor 
enhances the antitumour activity of CHK2 inhibition in human 
DLBCL.
Results
ERK1/2  and  CHK2  are  highly  expressed  in  human  DLBCL. 
To examine the expression of both ERK1/2 and CHK2 in human 
DLBCL, we performed immunohistochemistry analysis to evaluate 
the  ERK1/2  and  CHK2  protein  levels  on  50  primary  DLBCL 
specimens and 24 reactive lymph nodes. The expression of ERK1/2 
and  CHK2  was  examined  in  the  adjacent  slides  from  the  same 
sample.  The  DLBCL  was  further  classified  into  germinal  centre 
B-cell (GCB) and activated B-cell (ABC) subtypes, according to 
well-accepted immunohistochemistry-based algorithms17,18. Based   
on the criteria defined in the Methods, the specimens were divided 
into three staining groups: negative, low and high. As summarized 
in  Table  1,  ERK1/2  levels  are  markedly  elevated  in  98%  of  all 
the  DLBCL  and  100%  of  the  GCB  subtype  DLBCL  samples  as 
compared with the normal GCB cells of the reactive lymph nodes 
(21%). CHK2 is also elevated in 100% of the GCB DLBCL samples 
as compared with the normal GCB cells of reactive lymph nodes 
(46%). Interestingly, our correlation analysis revealed that ERK1/2 
expression levels in human DLBCL samples are strongly correlated 
with CHK2 protein levels (Pearson correlation coefficient ρ = 0.737, 
P < 0.0001). Representative sections of human DLBCL arrays are 
shown in Figure 1a. These data indicate that increased coexpression 
of ERK1/2 and CHK2 may be associated with the development of 
DLBCL. These data were further confirmed by western blot analysis 
in normal B cells and DLBCL cells (Fig. 1b). Together, ERK1/2 and 
CHK2 protein levels appear to be elevated in the vast majority of 
DLBCL, supporting their value as potential therapeutic targets.
Inhibition of ERK and CHK2 increases DLBCL cells apoptosis. 
It has been reported that inhibition of CHK2 expression attenu-
ated DNA damage-induced cell cycle checkpoints and enhanced 
apoptotic activity in HEK293 cells10,19. We asked whether inhibition   
Table 1 | Immunohistological analysis of ERK1/2 and CHK2 expression in DLBCL and normal GCB cells.
Samples No. ERK1/2 CHK2
N* Low High % ( + ) N* Low High % ( + )
DLBCL 50 1 6 43 98 0 19 31 100
  GCB subtype 11 0 2 9 100 0 4 7 100
  ABC subtype 39 1 5 33 97 0 15 24 100
normal GCB cells 24 20 4 0 17 13 11 0 46
*N, negative stainingARTICLE     
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of CHK2 would induce apoptosis in DLBCL cells. The CHK2 Inhib-
itor II shows 1,000-fold greater selectivity for the CHK2 serine/
threonine kinase than for the Cdk1/B and CK1 kinases and was first 
discovered to be a potent, selective small molecule showing radio-
protection towards human T cells20. CHK1 and CHK2 are structur-
ally unrelated yet functionally belong to the checkpoint kinase fam-
ily1. Therefore, we compared CHK1 phosphorylation with CHK2 
phosphorylation after CHK2 Inhibitor II treatment. Phosphoryla-
tion of CHK2 at Thr68 by ATM functions as a surrogate marker 
for CHK2 activation11,21. We found that different doses of CHK2 
inhibitor II specifically inhibit CHK2 phosphorylation at Thr68 at 
different time course, but not CHK1 phosphorylation (Fig. 2a,b). 
These data indicated that the CHK2 inhibitor II is specific for the 
inhibition of CHK2 activity. Exposure of SUDHL4, SUDHL6 and 
Farage cells to 5 µM CHK2 inhibitor II resulted in the apoptosis 
of less than 30% cells (Fig. 2c). We previously demonstrated that   
less than 30% DLBCL cells underwent apoptosis when exposed to 
20 µM of a novel ERK inhibitor14. Because DLBCL has two major 
subtypes (ABC versus GC), we subsequently examined the efficacy 
of combining CHK2 inhibitor II with ERK inhibitor in both ABC   
(for  example,  OCI-LY3)  and  GC-type  (Farage,  SUDHL4  and 
SUDHL6) cells. Treatment with combination of CHK2 inhibitor II 
and ERK inhibitor resulted in substantially more apoptosis com-
pared with treatment of either drug alone (Fig. 2c). Similar result was   
obtained in OCI-LY3 cells (Supplementary Fig. S1). DNA DSBs are 
demonstrated by examining the phosphorylation of histone H2AX 
on  Ser139  residues  (designated  γH2AX)15.  Exposure  to  either 
the ERK inhibitor or CHK2 inhibitor II alone induced a modest 
increase  in  H2AX  phosphorylation,  whereas  co-administration 
of both inhibitors dramatically increased H2AX phosphorylation. 
Apoptosis  by  the  combination  of  these  two  inhibitors  was  also   
demonstrated by examining PARP cleavage (Fig. 2d).
ERK and CHK2 physically interact with each other in DLBCLs. 
To  better  understand  the  relationship  between  ERK  and  CHK2 
in  vivo,  we  conducted  double-immunofluorescence  analysis  of 
ERK1/2 and CHK2 in human primary DLBCLs to detect their co-
localization. As shown in Figure 3a, CHK2 was localized to both 
the cytoplasmic and nuclear factions of DLBCLs, and ERK was 
predominately localized in the cytoplasm of DLBCLs. In addition, 
endogenous ERK and CHK2 were predominately co-localized in 
the cytoplasm of human DLBCLs. We next examined whether ERK 
physically associated with CHK2. We were able to detect the recip-
rocal co-immunoprecipitation of endogenous ERK1/2 with CHK2 
in Farage, SUDHL4 and SUDHL6 cells (Fig. 3b). Consistent with 
their  co-localization,  the  endogenous  ERK  and  CHK2  proteins 
co-immunoprecipitated  predominately  from  the  cytoplasm  frac-
tion of SUDHL6, Farage and OCI-LY3 cells (Fig. 3c; Supplemen-
tary Fig. S2a). To further confirm this interaction and to demon-
strate a direct physical interaction, in vitro glutathione S-transferase 
(GST) fusion protein pull-down assays were performed. We showed   
that the GST–ERK2 fusion protein was able to pull down CHK2 
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Figure 1 | ERK1/2 and CHK2 protein levels are elevated in human 
DLBCLs. (a) Representative fields of reactive germinal centre B-cell 
centroblasts and DLBCL tissue arrays immunohistochemically stained 
with anti-CD20, anti-CHK2 and anti-ERK1/2 antibodies as indicated. Low 
(original magnification, X20) and high (original magnification, X400) 
power views of CD20, CHK2, and ERK1/2 expression in reactive germinal 
centre B-cell centroblasts and DLBCL cells (immunoperoxidase stains). 
H&E staining was used for morphologic examination. (b) The correlation 
between ERK1/2 and CHK2 expression was shown in normal B cells and 
DLBCL cells. Five cases of normal B cells from different donors and seven 
DLBCL cells were lysed and subjected to the western blot analysis with  
the indicated antibodies. 1–5, normal B cells from different donors. 6,  
oCI-LY3; 7,suDHL4; 8, suDHL6; 9, Farage; 10, Pfeiffer; 11, Toledo; 12, 
Karpars-422.
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Figure 2 | Inhibition of ERK and CHK2 increases cell apoptosis. (a) The 
specificity of CHK2 inhibitor II. Farage and suDHL6 cells were treated  
with different doses of CHK2 inhibitor II in RPmI 1640 complete medium 
for 4 h. The levels of pCHK1, CHK1, pCHK2 and CHK2 in the total cell 
lysates were monitored by immunoblotting with the indicated antibodies. 
(b) Farage and suDHL6 cells were treated with 5 µm CHK2 inhibitor II 
in RPmI 1640 complete medium for different time course. The levels of 
pCHK1, CHK1, pCHK2 and CHK2 were examined by immunoblotting.  
(c) suDHL4, suDHL6 or Farage cells were exposed to 5 µm CHK2 inhibitor 
II or 20 µm ERK inhibitor alone or in combination for 72 h after which 
the percentage of apoptotic cells was determined by Annexin V analysis 
as described in methods. Data show means and s.d. from at least three 
separate experiments. P values were calculated using a paired student  
t-test. **Indicates values significantly greater (P < 0.01) than treatment  
with either agent alone. (d) Farage or suDHL6 cells were treated as 
described in c, after which whole cells were lysed and subjected to western 
blot analysis to monitor expression of γH2AX and cleavage of PARP.  
CF, cleavage fragments.ARTICLE
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(Fig. 3d). Taken together, these data establish the physical inter-
action between ERK1/2 and CHK2.
Thr  68  of  CHK2  mediates  the  interaction  between  ERK  and 
CHK2. Because CHK2 inhibitor II modestly induced the apop-
tosis of DLBCL cells, we asked whether CHK2 inhibition could 
affect the interaction between ERK and CHK2. Different doses of 
CHK2 inhibitor II dramatically diminished the physical interaction 
between ERK and CHK2 (Fig. 4a). Because the CHK2 inhibitor II   
specifically inhibits CHK2 phosphorylation at Thr68, this indicated 
that CHK2 phosphorylation at Thr68 is involved in the physical   
interaction between ERK and CHK2. We examined the CHK2 Thr68 
to Ala (T68A) mutant that was established previously22. Due to high 
levels of CHK2 protein in DLBCL cells and the technical difficulty 
in  transfecting  SUDHL4  and  SUDHL6  cells  using  liposomal  or   
electroporation methods, we expressed CHK2 wild type (WT) and 
its mutant T68A in both HEK293 and HeLa cells. Wild-type CHK2 
co-immunoprecipitated with ERK2, but the mutant CHK2 T68A 
did not (Fig. 4b). These results are further corroborated by GST   
pull-down  experiments.  Figure  4c  shows  that  the  GST–ERK2   
protein can pull down CHK2 WT but not the T68A mutant. Mimic-
king T68 phosphorylation with a negatively charged amino-acid 
Asp (T68D) promoted ERK interaction with CHK2 (Fig. 4d). In 
addition,  IR,  which  enhances  CHK2  T68  phosphorylation,  also 
increases their interaction (Fig. 4e). Together, these data demon-
strated that Thr68 phosphorylation is required for the interaction 
between ERK and CHK2.
CHK2 negatively regulates ERK activity. The interaction of CHK2 
and ERK suggests that they may regulate each other and ERK may 
be involved in CHK2-mediated DNA damage responses. This is also 
supported by our observation that ERK inhibitor potentiates CHK2 
inhibitor-induced cell apoptosis. However, it is still unclear how these 
two proteins regulate each other and why co-treatment with ERK 
and CHK2 inhibitors increased cell apoptosis. To begin to address 
these questions, we next assessed whether inhibition of CHK2 regu-
lates ERK. The CHK2 inhibitor II decreases CHK2 phosphorylation 
at Thr68 but increases ERK phosphorylation in SUDHL6, Farage and 
OCI-LY3cells (Fig. 5a; Supplementary Fig. S2b). Furthermore, when 
CHK2 was genetically modified to inhibit Thr68 phosphorylation, a 
similar result was observed. Figure 5b showed that mutant T68A acti-
vated ERK but CHK2 WT failed to do so. In contrast, the phospho-
rylation-site mimic mutant T68D decreased ERK phosphorylation 
compared with CHK2 WT (Fig. 4d). These data indicated that ERK 
activity is regulated by CHK2 and the disruption of the physical 
interaction between ERK and CHK2 is necessary for the activation 
of ERK. Knockdown of CHK2 by its specific siRNA decreased CHK2 
protein level and its phosphorylation; however, it also enhanced ERK 
phosphorylation (Fig. 5c). We next examined how ERK phosphory-
lation was affected when CHK2 phosphorylation was increased. It 
has been previously reported that etoposide is a potent activator of 
the DNA damage-signalling pathway23,24. Figure 5d shows that when 
CHK2  phosphorylation  was  increased  after  etoposide  exposure,   
ERK  phosphorylation  was  decreased.  Knocking  down  of  CHK2 
attenuates the regulation of ERK by etoposide (Fig. 5e). In addition, 
while CHK2 phosphorylation at Thr68 was enhanced by IR, ERK 
phosphorylation was also decreased (Fig. 4e).
We  next  investigated  whether  CHK2  directly  inhibits  ERK   
activity in  vitro.  GST–CHK2–KD is  defective  for  kinase  activity 
because of substitution of the catalytically essential Asp347 residue 
with Ala25. This mutation prevents autophosphorylation of CHK2 
kinase activity25. In Figure 5f, in vitro kinase assays showed ERK2 
and  CHK2  WT  can  autophosphorylate  and  phosphorylate  the 
generic kinase substrate, myelin basic protein (MBP). Interestingly, 
CHK2–KD was able to inhibit ERK2’s ability to phosphorylate MBP 
but had no apparent effect on ERK2 autophosphorylation, indicat-
ing that ERK2 catalytic activity was intact. These findings indicate 
that  CHK2  can  directly  inhibit  ERK2’s  ability  to  phosphorylate 
downstream  substrates  by  an  activity-independent  mechanism. 
Together, these findings establish that CHK2 negatively regulates 
ERK and suggest that inhibition of CHK2 is most effective in killing 
DLBCL cells if ERK functions are also inhibited.
ERK inhibition enhances the activity of CHK2 inhibitors in vivo. 
Next,  we  examined  whether  CHK2  inhibition  cooperated  with   
ERK inhibition in the treatment of DLBCL tumours in vivo. We 
established  SUDHL6  DLBCL  xenografts  in  28  severe  combined 
immunodeficient (SCID) mice (7 mice per group). Once the tumour 
reached the size of 60–163 mm3, we treated the mice every other 
day intraperitoneally with either vehicle, ERK inhibitor (5 mg kg − 1), 
CHK2 inhibitor II (1 mg kg − 1), or both ERK inhibitor and CHK2 
inhibitor II for 20 days. At these doses, no lethal toxicity, signifi-
cant weight loss or any gross abnormalities were observed among 
treated animals (data not shown). No evidence of tissue damage 
was detected by microscopic examination of mouse organs (Supple-
mentary Fig. S3). Both 5 mg kg − 1 ERK inhibitor and 1 mg kg − 1 CHK2 
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(a) Co-localization of ERK1/2 and CHK2 in human lymphoma tissues. 
Double immunofluorescent staining for CHK2 (green) and ERK (red) 
at X600 magnification indicates that there is strong overlapping in 
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inhibitor II modestly inhibited tumour growth but combined treat-
ment with ERK inhibitor and CHK2 inhibitor II resulted in a statis-
tically significant suppression of tumour growth (Fig. 6a,b). Moreo-
ver, western blot analysis revealed that combined treatment with the 
ERK inhibitor and CHK2 inhibitors caused a striking increase in   
H2AX phosphorylation and PARP cleavage (Fig. 6c). This further 
confirmed  that  co-administration  of  the  CHK2  inhibitor  mark-
edly  potentiates  DNA  damage  in  DLBCL  cells  exposed  to  ERK 
inhibitor and this event precedes induction of extensive apoptosis. 
Immunohistochemical  analysis  of  tumour  sections  showed  that   
co- administration  of  the  ERK  and  CHK2  inhibitors  markedly 
reduced expression of the cell proliferation marker Ki67 whereas 
each inhibitor alone had slight impact (Fig. 6d). In addition, TdT-
mediated  dUTP  nick  end  labelling  (TUNEL)  assay  showed  that 
the combined treatment with ERK inhibitor and CHK2 inhibitor 
II resulted in greater induction of apoptosis compared with either 
inhibitor alone (Fig. 6d).
Inhibition of ERK and CHK2 in human DLBCLs cells. Because 
combined treatment of the CHK2 and ERK inhibitors is a candi-
date treatment strategy for human lymphomas, we wished to exa-
mine the effects of this combination on the apoptosis and viability 
of primary DLBCLs from human patients. Single cell suspensions 
were generated from two confirmed DLBCL lymph node biopsy 
specimens and exposed to either control (DMSO), ERK inhibitor, 
CHK2 inhibitor II or the combination of both inhibitors for 48 h. 
Co-treatment of the ERK and CHK2 inhibitors enhanced apoptosis 
of human primary DLBCL cells as compared with either inhibitor 
alone (Fig. 7a). Four cases of normal B cells are unresponsive to the 
inhibitor alone and the combination (Supplementary Fig. S4a). To 
further exclude the toxicity of the inhibitors in different cell pheno-
types, immortalized untransformed fibroblasts (ID:GM04390, skin) 
were examined and insensitive to the combination of the inhibitors 
(Supplementary Fig. S4b). In addition, combined treatment with 
the  ERK  inhibitor  and  CHK2  inhibitor  II  dramatically  reduced 
cells viability whereas the inhibitor administered individually had 
less effect (Fig. 7b). Therefore, these results are consistent with our 
DLBCL cell line and xenograft data and further support the concept 
that inhibition of ERK functions potentiates the antitumour activity 
of CHK2 inhibition in human DLBCLs.
Discussion
Our  study  addresses  the  therapeutic  targeting  and  functional   
interaction between ERK and CHK2 in the setting of DLBCL. Our 
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immunohistochemical analysis on tissue microarrays showed that 
both ERK and CHK2 protein levels were elevated in the majority   
of human DLBCL samples as compared with the normal GCB cells 
of  reactive  lymph  nodes.  This  supports  their  value  as  potential 
therapeutic targets. The potential utility of ERK targeted therapy is 
supported by our previous data that treatment with the ERK inhibi-
tor has marked antitumour activity in human DLBCL xenograft  
models14. Previous reports using western blotting have shown that 
CHK2 protein expression level is high in most primary diffuse large 
B-cell lymphomas (41/43), and absent or very low in six samples 
of  normal  peripheral  blood  lymphocytes26,  which  is  consistent 
with our results. However, their western blot data also showed that 
CHK2 protein levels in DLBCL samples was similar to that in 6 
reactive lymphoid tissues26. This discrepancy may be explained by 
the presence of other cell types such as T cells, follicular dendritic 
cells and stromal cells in addition to reactive B cells in the reac-
tive germinal centre that was examined by western blot analysis. 
Furthermore, we were able to demonstrate using IHC that CHK2 
levels of GC subtype of DLBCL are also elevated as compared with 
the normal GC cells. The mechanism for elevated CHK2 protein 
levels  in  DLBCL  is  still  poorly  described.  Further  experiments 
are  necessary  to  investigate  CHK2  modification  and  the  CHK2   
signalling network in DLBCL.
It has been previously reported that Raf/MEK/ERK signalling 
was linked to DNA damage response and DNA repair through 
an ATM-dependent process13. This indicates that ERK is related 
with  CHK2  signalling.  We  for  the  first  time  demonstrate  the 
physical  interaction  between  ERK1/2  and  CHK2  and  their  co-
localization in primary DLBCL cells. In addition, the interaction 
between CHK2 and ERK is disrupted by both CHK2 inhibitor II 
and CHK2 mutation at Thr68. We also found that ERK protein 
level is strongly correlated with the level of CHK2 protein (Pearson 
correlation coefficient ρ = 0.737). These data together suggest that 
the interaction between ERK and CHK2 is likely to have biological 
relevance in DLBCL. This is further supported by our finding that 
inhibition of CHK2 phosphorylation of T68 disrupted the inter-
action between these two proteins. Thus, the functional interac-
tion between ERK and CHK2 requires CHK2 phosphorylation. 
However, the ability for CHK2 to inhibit ERK phosphorylation of 
downstream substrates is kinase-independent and likely involves 
steric hindrance of ERK accessibility to substrate proteins. Deter-
mination of the molecular contacts involved in CHK2 interactions 
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with ERK2 will provide insight into how CHK2 negatively regu-
lates ERK functions.
We found that inhibition of CHK2 activity modestly induced 
apoptosis of SUDHL4, SUDHL6 and Farage cells. CHK2 inhibition 
also induced DNA breaks by itself, manifested by increased phos-
phorylation of histone H2AX at serine 139. Inhibition of CHK2 
expression has also been found to attenuate DNA damage-induced 
cell cycle checkpoints and to enhance apoptotic activity in HEK293 
cells19. Targeting of CHK2 with siRNA enhanced apoptosis follow-
ing induction of DNA damage by IR or doxorubicin, and inhibited   
the growth of resistant in vivo tumours9,12. Thus, induction of DNA 
damage  by  CHK2  inhibition  may  contribute  to  its  antitumour   
activity. It should be noted that the response of a tumour to CHK2 
manipulation depends on a specific cellular context. An intrigu-
ing proposal put forth by Laurent Antoni and his colleagues is that 
CHK2 kinase is similar to the two sides of the same coin10. In the case 
of wild-type CHK2 tumours that possess other defects in checkpoint 
and repair pathways, short-term inhibition of CHK2 could have thera-
peutic value10. In contrast, in those tumours where CHK2 function 
is diminished or eliminated, inhibition of other proteins involved 
in checkpoint and repair pathways might be lethal10. Defining how 
CHK2 kinase elicits such distinct cellular outcomes as cell survival 
through DNA repair versus apoptosis or senescence, depending on 
the genetic background is a critical area of investigation.
The Ras/MEK/ERK signalling cascade is key pathway implicated in 
hematopoietic malignant cells survival signalling. Under physiologic 
conditions,  ERK  activation  stimulates  transcription  leading  to  cell 
cycle progression and proliferation by activated growth factor signal-
ling. ERK1/2 signalling has been implicated in attenuation of DNA 
damage  through  positive  regulation  of  DNA  repair  mechanism15. 
Although the CHK2 inhibitor induced DNA breaks and damage, an 
unexpected finding was that inhibition of CHK2 activity leads to acti-
vation of ERK, which may preserve cell survival and proliferation. This 
provides a plausible explanation for the modest induction of cell apop-
tosis by CHK2 inhibitor and suggests that activation of ERK signalling 
pathway may represent a compensatory response to CHK2 inhibition. 
In other words, functional CHK2 may be required for cells to survive 
the basal level of genomic instability known to be present in many 
malignancies. However, the resulting ERK activation in response to 
CHK2 inhibition provides a potent survival signal that attenuates the 
apoptotic drive. This also provides a molecular mechanism by which 
interruption of ERK functions potentiates the killing of DLBCL cells 
treated with the CHK2 inhibitor. Similarly, the CHK1 inhibitor, UCN-
01, also triggers compensatory activation of the prosurvival Ras/MEK/
ERK cascade in various tumour cell types, including human multiple 
myeloma cells15. Our data is consistent with the previous report that 
activation of ATM by radiation downregulates phospho-ERK1/2 and 
its downstream signalling in both cell culture and tumour models27.
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It is imperative to identify drugs that can improve the efficacy and 
reduce the toxicity of standard anti-lymphoma therapy28. We have 
demonstrated that a novel ERK2 inhibitor enhances the antitumour 
activity of CHK2 inhibition in a human DLBCL xenograft model 
and primary DLBCL cells from human patients. It is also worth not-
ing that there was no evidence of toxicity in animals treated with 
either  ERK  or  CHK2  inhibitors  alone  or  in  combination.  Addi-
tionally, exposure of normal human B cells and fibroblasts to both 
ERK and CHK2 inhibitors revealed little cytotoxicity. The lack of 
apparent toxicity to normal tissues makes targeting both ERK and 
CHK2 signalling an attractive clinical approach. Moreover, making 
this potential combination clinically appealing is the fact that CHK2 
activation occurs after exposure to commonly used chemotherapeu-
tic agents in DLBCL therapy as well as IR, suggesting that incor-
porating this dual inhibitor strategy could increase the therapeutic 
efficacy of standard regimens without increasing side effects.
In summary, we have shown a positive correlation between ERK 
and CHK2 expression in human DLBCL. ERK physically interacts 
with CHK2 and inhibition of CHK2 activates ERK, which may serve 
as a compensatory response to enhance cell survival. Thus, com-
bined inhibition of ERK and CHK2 exerts a potent anti-tumour 
effect in a human DLBCL xenograft model and primary DLBCL cells   
from human patients and may provide a therapeutic advantage.   
Whether  these  findings  can  be  extended  to  other  types  of   
lymphoma is unknown at present and warrants further investiga-
tion. Our study demonstrates the mechanistic basis for the thera-
peutic targeting of DLBCLs with inhibition of both ERK and CHK2 
and provides a rationale for using this combinatorial therapy.
Methods
Cell culture and treatments. DLBCL (SUDHL4, SUDHL6 and Farage) cells were 
grown in RPMI 1640 (Invitrogen) containing 10% fetal bovine serum and 1%  
Penicillin/Streptomycin. HeLa and HEK293 cells were grown in DMEM (Invitrogen) 
containing 10% fetal bovine serum. ERK inhibitor no. 76 (3-(2-aminoethyl)- 
5-((4-ethoxyphenyl) methylene)-2,4-thiazolidine- dione, HCl) was purchased  
from Calbiochem. CHK2 inhibitor II (2-(4-(4-chlorophenoxy) phenyl)-1H- 
benzimidazole-5-carboxamide hydrate) was from Sigma Aldrich. Myc (or Flag)-
Wild-type CHK2 (WT), and Myc (or Flag) -T68A CHK2 constructs were gifts 
from Dr Sheau-Yann Shieh. GFP–WT CHK2, GFP–T68D CHK2, GST–WT CHK2 
and GST–Kinase inactive CHK2(KD) constructs were kindly provided by  
Drs Bahassi and Stambrook. HeLa and HEK293 cell transfections were done with 
Lipofectamine 2000 (Invitrogen).
Specific oligo siRNAs for CHK2, and the negative siRNA control were  
obtained from Santa Cruz. Transfection experiments were performed using  
Amaxa Nucleofector kit V (Amaxa), program A-020.
Primary cells. De-identified tissue samples were obtained from patients in  
accordance with the guidelines and approval of the University of Maryland Medical 
School Institutional Review Board and conform to the Declaration of Helsinki. Sin-
gle-cell suspensions were obtained from lymph node biopsies by physical disruption 
of tissues (using scalpels and cell restrainers), followed by cell density ficoll-gradient 
separation. Cell number and viability were determined by trypan blue dye exclusion 
with at least 70–80% viable cells before treatment exposure. Primary cells were 
cultivated in medium containing 80% RPMI and 20% human serum supplemented 
with antibiotics, l-glutamine and HEPES for 48 hours  + / −  drug treatment. Cells 
were exposed to varying doses of the ERK and/or CHK2 inhibitors as indicated.
Assessment of cell apoptosis and percentage non-viable cells. Cells were 
seeded at equal density and then treated with the ERK and/or CHK2 inhibitors in com-
plete RPMI 1640 medium. Forty-eight or seventy-two hours after drug treatment, cells 
were collected and apoptosis was analysed by flow cytometry using Annexin V staining 
kit (Southern Biotech). After designated treatments, cells were stained with Trypan 
Blue (Sigma-Aldrich). The numbers of non-viable cells were determined by counting 
the cells that showed trypan blue uptake using a hemocytometer. Statistical significance 
between experimental conditions was determined using the Student’s t-test.
Co-immunoprecipitation and immunoblotting. After the treatment, the cells 
were lysed in the buffer (20 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Triton X-100, 1 mM Na3VO4, 1 mg ml − 1 aprotinin, 1 mg ml − 1 
leupterin and 1mM PMSF). Insoluble material was removed by centrifugation, 
and antibodies were added to lysates for 1 h at 4 °C. Antibodies were collected with 
protein A or protein G-sepharose beads, and protein complexes were washed three 
times at 4 °C with the lysis buffer. Immunoblotting was performed using standard 
methods. Rabbit polyclonal anti–CHK2 (Santa Cruz), Anti-pCHK2, anti-pERK1/2, 
anti-ERK1/2 (Cell Signaling) and anti-PARP (Enzo) antibodies were used at 
1:1,000, whereas anti-γH2AX (Millipore) and anti-actin (C2, Santa Cruz) were 
used at 1:5,000.
Glutathione S-transferase fusion protein pull-down assays. GST fusion 
proteins were expressed in Escherichia coli BL21(DE3) cells, and purified using 
glutathione-Sepharose beads. Briefly, the GST fusion proteins were coupled to 
glutathione beads at 4 °C for 1 h and then washed three times with the lysis buffer. 
The immobilized GST fusion proteins were incubated with the cell lysates for 1 h at 
4 °C. The beads were washed with the lysis buffer four times and then the protein 
complexes were loaded in 10% SDS–PAGE, followed by immunoblotting.
In vitro kinase assay. ERK2 was expressed in bacteria and purified as previ-
ously described29. The GST-tagged Chk2 wild type and kinase inactive mutant 
(KD) was obtained from Drs Bahassi and Stambrook and expressed in bacteria14. 
ERK2 wild type (2 µg) and 0.5 µg MBP were incubated in the presence or absence 
of 1 µg GST–Chk2 wild type or inactive GST–Chk2 (KD) for 15 min at 300C in 
50 mM Tris–HCl, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Brij 35 (pH 7.5) 
containing 20 µM cold ATP and 2 µCi γ-32P–ATP. Reactions were stopped with an 
equal volume of 2×SDS–PAGE sample buffer, and the proteins were resolved by 
SDS–PAGE, stained with Coomassie Blue, and phosphorylation of Chk2, ERK2 
and MBP was determined by autoradiography or phosphoimager analysis.
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Figure 7 | ERK and CHK2 inhibitors enhance apoptosis induction in 
primary human DLBCL cells. (a) single-cell suspensions were obtained 
from lymph node biopsies of patients diagnosed with DLBCL and were 
treated with Dmso, ERK inhibitor and CHK2 inhibitor II alone or in 
combination for 48 h after which the percentage of apoptotic cells 
was determined by Annexin V analysis as described in methods. Flow 
cytometric profile was showed in the left panel. Pt 1, patient one; Pt 2,  
patient two. (b) single-cell suspensions were treated as described 
in the (a). After the treatment, the percentages of non-viable cells 
were determined by trypan blue dye uptake in a hemocytometer. Data 
represents mean and s.d. from three separate experiments. P values were 
calculated using a student t-test. *P < 0.05; **P < 0.01.ARTICLE     
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Tissue microarrays and protein detection. Eight tissue microarrays were purchased 
from Biomax (#LM801). These arrays included a total of 10 reactive lymph nodes, 54 
DLBCL and 6 other types of lymphoma. Four more DLBCL were excluded because 
of fall-off of the tissue sections during staining. Six of the 10 reactive lymph nodes 
were excluded in this analysis because of their lack of germinal centres. In addition, 20 
reactive lymph node samples were provided by the UMGCC Pathology Biorepository 
and Research Core to serve as normal GCB controls. Human sample studies have been 
approved by the University of Maryland Medical School Institutional Review Board and 
conform to the Declaration of Helsinki. The paraffin sections were routinely stained 
with hematoxylin-eosin (H&E) reagents for morphologic examination. The Vectastain 
Elite ABC kit, purchased from Vector Laboratories, was used for immunohistochemical 
analysis.The paraffin sections were incubated overnight at 4 °C with the primary anti-
body. Anti-Ki67 and anti-CD20 antibodies (Dako) were used at 1:1,000. Anti-CD10, 
anti-BCL6 and anti-MUM1 antibodies (Abcam) were used at 1:20 and anti-FOXP1 an-
tibody (Abcam) was used at 1:1,200. Anti-ERK1/2 antibody (Cell Signaling) was used at 
1:300 and anti-CHK2 antibody (Santa Cruz) was used at 1:200. Slides were then treated 
with biotinylated secondary antibody and incubated with performed avidin–peroxidase 
complex. The sections were counterstained with hematoxylin, dehydrated, and mount-
ed. Appropriate positive and negative controls were included in each assay. Immunohis-
tochemical staining was evaluated independently by two hematopathologists (XFZ and 
SL with an inter-observer consistency  > 90%), according to our scaled criteria: 0,  < 25% 
neoplastic cells staining; 1 + , 26–50% neoplastic cells staining; 2 + , 50–75% neoplastic 
cells staining; 3 + ,  > 75% neoplastic cells staining. Based on the intensity of staining, 
the lymphomas were also divided into negative, weak, and strong staining patterns. 
Because the staining intensity may vary from assay to assay, our scaled criteria overrule 
the staining intensity, if only small number of lymphoma cells show strong staining. 
Occasional inter-observer inconsistencies were reconciled by re-reviewing together by 
the two hematopathologists to reach agreement. In combination, the lymphomas were 
roughly divided into negative (0 and/or negative), low (1 +  and/or weak) and high (2 + , 
3 +  and strong) expresser groups. The images were acquired with a Nikon eclipse 50i 
microscope (Nikon Instruments) and formatted with Adobe PhotoShop CS software.
For fluorescence double staining, the section was treated as above and first 
stained with mouse monoclonal anti-ERK1/2 antibody (Cell Signaling, 1:300). 
After biotin blocking, the section was then stained with rabbit polyclonal  anti-
CHK2 antibody (Santa Cruz, 1:200). The sections were then washed with PBS and 
incubated with goat anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 
568 at a concentration of 1:200 each. The stained sections were mounted using 
Vectashield mounting medium (Vector). Control sections were similarly processed, 
except that the primary antisera were omitted, which yielded no staining. Images 
were captured using an Olympus FV1000 confocal microscope (Olympus) and 
processed with the Olympus Fluoview Version 1.7c software.
In vivo tumour growth in the xenograft models. All procedures involving animals 
were approved by the Institutional Animal Care and Use Committee of the University of 
Maryland. Female SCID Beige mice were housed in a pathogen-free environment un-
der controlled conditions of light and humidity and received food and water ad libitum. 
SUDHL6 cells (1.2×106) were resuspended in 100 µl PBS and then mixed with an equal 
volume of Matrigel. The mixture was s.c. injected into the left and right dorsal flanks of 
5- to 7-week-old female SCID mice. When the tumour reached the size of 60–163 mm3, 
the treatment was administered intraperitoneally every other day for a total of 20 days. 
ERK inhibitor no. 76 in DMSO was freshly prepared in PBS for a final dose of 5 mg kg − 1. 
CHK2 inhibitor II in alcohol was diluted in PBS for a final dose of 1 mg kg − 1. Injection 
of the vehicle alone was used as a control. Tumours were measured three times a week 
with calipers, and tumour volumes were calculated by the formula ½×r1
2×r2 (r1 < r2). At 
the moment of death, tumours were collected for further analysis. The significance of 
differences between treatment arms was determined using the Student’s t-test. 
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